1588-1589 / 2063
Take home messages
•
Numerous trials in progress combining RT +
targeted agents
•
Challenges
•
Bridge between preclinical and clinical models (tumor
growth delay vs tumor control (TCD
50
))
•
Translational research
•
Biomarkers
•
Trial design – patient stratification
•
New toxicities – late effects